Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.15.6145

Expression of Toll-like Receptor 9 Increases with Progression of Cervical Neoplasia in Tunisian Women - A Comparative Analysis of Condyloma, Cervical Intraepithelial Neoplasia and Invasive Carcinoma  

Fehri, Emna (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases)
Ennaifer, Emna (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases)
Ardhaoui, Monia (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases)
Ouerhani, Kaouther (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases)
Laassili, Thalja (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases)
Rhouma, Rahima Bel Haj (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases)
Guizani, Ikram (HPV Unit Research. Laboratory of Molecular Epidemiology and Experimental Pathology Applied to Infectious Diseases)
Boubaker, Samir (Department of Human and Experimental Pathology, Pasteur Institute of Tunis)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.15, 2014 , pp. 6145-6150 More about this Journal
Abstract
Toll-like receptors (TLRs) are expressed in immune and tumor cells and recognize pathogen-associated molecular patterns. Cervical cancer (CC) is directly linked to a persistent infection with high risk human papillomaviruses (HR-HPVs) and could be associated with alteration of TLRs expression. TLR9 plays a key role in the recognition of DNA viruses and better understanding of this signaling pathway in CC could lead to the development of novel immunotherapeutic approaches. The present study was undertaken to determine the level of TLR9 expression in cervical neoplasias from Tunisian women with 53 formalin-fixed and paraffin-embedded specimens, including 22 samples of invasive cervical carcinoma (ICC), 18 of cervical intraepithelial neoplasia (CIN), 7 of condyloma and 6 normal cervical tissues as control cases. Quantification of TLR9 expression was based on scoring four degrees of extent and intensity of immunostaining in squamous epithelial cells. TLR9 expression gradually increased from CIN1 (80% weak intensity) to CIN2 (83.3% moderate), CIN3 (57.1% strong) and ICC (100% very strong). It was absent in normal cervical tissue and weak in 71.4% of condyloma. The mean scores of TLR9 expression were compared using the Kruskall-Wallis test and there was a statistical significance between normal tissue and condyloma as well as between condyloma, CINs and ICC. These results suggest that TLR9 may play a role in progression of cervical neoplasia in Tunisian patients and could represent a useful biomarker for malignant transformation of cervical squamous cells.
Keywords
Toll-like receptors; TLR9; cervical cancer; immunohistochemistry;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Akira S (2009). Pathogen recognition by innate immunity and its signaling. Proc Jpn Acad Ser B Phys Biol Sci, 85, 143-56.   DOI   ScienceOn
2 Al Moustafa AE, Al-Awadhi R, Missaoui N, et al (2014). Human papillomaviruses-related cancers: Presence and prevention strategies in the Middle east and North African Regions. Hum Vaccin Immunother, 30, 10.
3 Andersen JM, Al-Khairy D, Inqalls RR (2006). Innate immunity at mucosal surface. Role of Toll-like receptor 3 and Toll-like receptor 9 in cervical epithelial cell response to microbial pathogens. Biol Reprod, 74, 824-31.   DOI
4 Bhattacharya D, Yusuf N (2012). Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment. Int J breast Cancer, 2012, 716564.
5 Boccardo E, Lepique AP, Villa LL (2010). The role of inflammation in HPV carcinogenesis. Carcinogenesis, 31, 1905-12.   DOI   ScienceOn
6 Bodelon C, Madeleine MM, Johnson LG, Du Q, Galloway DA, Malkki M, Petersdorf EW, Schwartz SM (2014). Genetic variation in the TLR and NF-кB pathways and cervical and vulvar cancer risk: a population-based case-control study. Int J Cancer, 134, 437-44.   DOI
7 Chang LS, Leng CH, Yeh YC, et al (2014). Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumorassociated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy. Mol Cancer, 13, 60.
8 Chen X, Wang S, Liu L, et al (2012). A Genetic Variant in the Promoter Region of Toll-Like Receptor 9 and Cervical Cancer Susceptibility. DNA Cell Biol, 31, 766-71.   DOI
9 Cheng YX, Qi XY, Huang JL, et al (2012). Toll-like receptor 4 signaling promotes the immunosuppressive cytokine production of human cervical cancer. Eur J Gynaecol Oncol, 33, 291-4.
10 Dai Q, Li XP, Chai L, Long HA, Yang ZH (2014). Polymorphisms of Toll-like receptor 9 are associated with nasopharyngeal carcinoma susceptibility. Tumour Biol, 35, 3247-53.   DOI
11 Daud II, Scott ME, Ma Y, et al (2011). Association between tolllike receptor expression and human papillomavirus type 16 persistence. Int J Cancer, 128, 879-86.   DOI
12 Decarlo CA, Rosa B, Jackson R, et al (2012). Toll-Like receptor transcriptome in the HPV-positive cervical cancer microenvironment. Clin Dev Immunol, 2012, 785825.
13 Doan HQ, Bowen KA, Jackson LA, Evers BM (2009). Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res, 29, 2473-78.
14 Domingos-Pereira S, Decrausaz L, Derre L, et al (2013). Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital tumor regression in mice. Mucosal Immunol, 6, 393-404.   DOI
15 El andaloussi A, Sonabend AM, Han Y, Lesniak MS (2006). Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia, 54, 526-35.   DOI   ScienceOn
16 Geller MA, Cooley S, Argenta PA, et al (2010). Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother, 59, 1877-84.   DOI
17 Hasimu A, Ge L, Li QZ, Zhang RP, Guo X (2011). Expressions of Toll-like receptors 3, 4, 7 and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women. Chin J Cancer, 30, 344-50.   DOI
18 Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, et al (2011). Study of TLR3, TLR4 and TLR9 in prostate carcinoma and their association with biochemical recurrence. Cancer Immunol Immunother, 60, 217-26.   DOI   ScienceOn
19 Hanley SJ, Yoshioka E, Ito Y, et al (2014). An exploratory study of Japanese fathers' knowledge of and attitudes towards HPV and HPV vaccination: does marital status matter? Asian Pac J Cancer Prev, 15, 1837-43.   과학기술학회마을   DOI   ScienceOn
20 Hasan UA, Bates E, Takeshita F, et al (2007). TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type16. J Immunol, 178, 3186-97.   DOI
21 Hirsch I, Caux C, Hasan U, Bendriss-Vermare N, Olive D (2010). Impaired Toll-like receptor 7 and 9 signaling : from chronic viral infections to cancer. Trends Immunol, 31, 391-7.   DOI
22 Karim R, Meyers C. Backendorf C, et al (2011). Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One, 6, 17848.   DOI
23 Kim WY, Lee JW, Choi JJ, et al (2008). Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer, 18, 300-5.   DOI   ScienceOn
24 Krug A, French A.R, Barchet W, et al (2004). TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity, 21, 107-19   DOI   ScienceOn
25 Liu L, Li YH, Niu YB, et al (2010). An apple oligogalactan prevents against inflammation and carcinogenesis by targeting LPS/TLR4/NF-kB pathway in a mouse model of colitis-associated colon cancer. Carcinogenesis, 31, 1822-32.   DOI
26 Lai ZZ, Ni-Zhang, Pan XL, Song L (2013). Toll-like receptor 9 (TLR9) gene polymorphisms associated with increased susceptibility of human papillomavirus-16 infection in patients with cervical cancer. J Int Med Res, 41, 1027-36.   DOI
27 Lee JW, Choi JJ, Seos ES, et al (2007). Increased Toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog, 46, 941-47.   DOI   ScienceOn
28 Li J, Kang LN, Qiao YL (2011). Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev, 12, 1149-53.
29 Lund J, Sato A, Akira S, Medzhitov R, Iwasaki (2003). A tolllikereceptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med, 198, 513-20.   DOI   ScienceOn
30 Mason KA, Hunter NR (2012). CpG plus radiotherapy: a review of preclinical works leading to clinical trial. Front Oncol, 2, 1-6.
31 Mai CW, Kang YB, Pichika MR (2013). Should a Toll-like receptor 4 (TLR-4) agonist antagonist be designed to treat cancer ? TLR-4 : its expression and effects in the most common cancers. Onco targets Ther, 6, 1573-87.
32 Moreno-Eutimio MA, Altamirano GA, Vargas-Hernandez VM (2013). Expression of toll-like receptor 9 in cervical intraepithelial neoplasia from Mexican women. J Cytol Histol, 4, 4.
33 Mvundura M, Tsu V (2014). Estimating the costs of cervical screening in high-burden Sub-Saharian African countries. Int J Gynaecol Obstet, 126, 151-5   DOI
34 Othman N, Othman NH (2014). Detection of human papillomavirus DNA in routine cervical scraping samples: use for a national cervical cancer screening program in a developing nation. Asian Pac J Cancer Prev, 15, 2245-9.   과학기술학회마을   DOI   ScienceOn
35 Ochi A, Graffeo CS, Zambrinis CP, et al (2012). Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest, 122, 4118-29.   DOI
36 Ohlschlager P, Spies E, Alvarez G, Quetting M, Groettrup M (2011). The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer, 128, 473-81.   DOI
37 Oliveira LB, Louvanto K, Ramanakumar AV, et al (2013). Cohort Study. Polymorphism in the promoter region of the Toll-like receptor 9 gene and cervical human papillomavirus infection. J Gen Virol, 94, 1858-64.   DOI
38 Pandey S, Mittal B, Srivastava M, et al (2011). Evaluation of Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in cervical cancer susceptibility. Mol Biol Rep, 38, 4715-21.   DOI
39 Roszak A, Lianeri M, Sowinska A, Jagodzinski PP (2012). Involvement of Toll-like Receptor 9 polymorphism in cervical cancer development. Mol Biol Rep, 39, 8425-30.   DOI
40 Sajadian A, Tabarraei A, Soleimanjahi H, et al (2014). Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine. Arch Virol.
41 Schmausser B, Andrulis M, Endrich S, Muller-Hermelink HK, Eck M (2005). Toll Like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol, 295, 179-85.   DOI   ScienceOn
42 Wagner H (2012). Innate immunity's path to the Nobel Prize 2011 and beyond. Eur J Immunol, 42, 1089-92.   DOI
43 Schmidt C (2006). Immune system's Toll-like receptors have good opportunity for cancer treatment. J Natl Cancer Inst, 98, 574-5.   DOI   ScienceOn
44 Sheyhidin I, Nabi G, Hasim A, et al (2011). Overexpression of TLR3, TLR4, TLR7 and TLR9 in oesophageal squamous cell carcinoma. World J Gastroenterol, 17, 3745-51.   DOI   ScienceOn
45 Spaner DE, Masellis A (2007). Toll like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia, 21, 53-60.   DOI
46 Wang C, Cao S, Yang Y, et al (2010). TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer, 10, 415.   DOI
47 Wang JL, Yang YZ, Dong WW, et al (2013). Application of human papillomavirus in screening for cervical cancer and precancerous lesions. Asian Pac J Cancer Prev, 14, 2979-82.   과학기술학회마을   DOI   ScienceOn
48 Wang YY, Li L, Wei S, et al (2013). Human papillomavirus (HPV) infection in women participating in cervical cancer screening from 2006 to 2010 in Shenzhen City, South China. Asian Pac J Cancer Prev, 14, 7483-87.   과학기술학회마을   DOI   ScienceOn
49 Werner J, Decarlo CA, Escott N, Zehbe I, Ulanova M (2012). Expression of integrins and Toll-like receptors in cervical cancer: effect of infectious agents. Innate Immun, 18, 55-69.   DOI
50 Weng Y, Wang Y, Shi Y, et al (2011). TLR9 expression and its role in chemosensitivity to DDP in human cervical cancer cells in vitro. Med Sci, 31, 550-4.
51 Zhou Q, Zhu K, Cheng H (2013). Toll-like receptors in human papillomavirus infection. Arch Immunol Immunother Exp, 61, 203-15.   DOI
52 Yang H, Zhou H, Feng P, et al (2010). Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res, 29, 92.   DOI   ScienceOn
53 Yu L, Wang L, Li M, et al (2010). Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother, 59, 1021-8.   DOI
54 Yu L, Wang L, Chen S. (2013). Dual character of Toll-like receptor signalling: pro-tumorigenic effects and anti-tumor functions. Bio Bio Acta, 1835, 144-54.
55 Zolini GP, Lima GK, Lucinda N et al (2014). Defense against HSV-1 in a murine model is mediated by iNOS and orchestrated by the activation of TLR2 and TLR9 in trigeminal ganglia. J Neuroinflammation, 30, 11-20.
56 Zur Hausen H (2009). Papillomavirus is the causation of human cancers- a brief historical account. Virology, 384, 260-5.   DOI
57 Hasan UA, Zannetti C, Parroche P, et al (2013). The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med, 210, 1369-87   DOI